BiotechTube

Zopapogene imadenovec (Zopa)

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Recurrent Respiratory Papillomatosis

Conditions

Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae

Trial Timeline

Jul 11, 2024 → Dec 2, 2028

NCT ID
NCT06538480

About Zopapogene imadenovec (Zopa)

Zopapogene imadenovec (Zopa) is a approved stage product being developed by Precigen for Recurrent Respiratory Papillomatosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06538480. Target conditions include Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae.

What happened to similar drugs?

5 of 20 similar drugs in Recurrent Respiratory Papillomatosis were approved

Approved (5) Terminated (0) Active (15)
✅Bevacizumab + Capecitabine + Everolimus + ExemestaneNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅Pidotimod + PlaceboAlmirallApproved
✅BaclofenBrain BiotechApproved
🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
🔄E7777 9 mcg/kgEisaiPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06538480ApprovedRecruiting

Competing Products

20 competing products in Recurrent Respiratory Papillomatosis

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
KPL-914Kiniksa PharmaceuticalsPhase 2
29
KPL-387Kiniksa PharmaceuticalsPhase 2
36
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
34
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
30
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
36
PLX3397Daiichi SankyoPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Drug Combination TherapySun PharmaceuticalPhase 2
42
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
Eribulin MesylateEisaiPre-clinical
26
Lenvatinib + EverolimusEisaiPhase 1/2
32
E7090EisaiPhase 2
42
LenvatinibEisaiPhase 2
42